[Ip-health] MSF responds to Medicines Patent Pool/ViiV Healthcare announcement

Joanna Keenan-Siciliano joanna.l.keenan at gmail.com
Wed Feb 27 08:14:20 PST 2013


The Medicines Patent Pool (MPP) has today announced a deal that would see
ViiV Healthcare's paediatric formulation of HIV treatment drug abacavir
licensed to the Pool. MPP's announcement can be found
here<http://www.medicinespatentpool.org/medicines-patent-pool-viiv-healthcare-collaborate-to-treat-paediatric-hiv/>
.

Médecins Sans Frontières responds to the announcement with the below quote:

“This licence shows welcome improvements over the previous licence the
Patent Pool signed with a pharmaceutical company, but it is disappointing
that ViiV is not including all developing countries in the agreement, given
the fragile and fragmented nature of the paediatric HIV medicines market.

While it’s encouraging to see ViiV taking steps towards greater
collaboration on access to paediatric formulations, the real breakthrough
we’re looking for is an agreement to make the company’s promising new drug
dolutegravir available to both adults and children in all developing
countries.

Efforts to increase transparency in voluntary licence negotiations,
including making the licence and its terms publicly available, are
appreciated.”

- Aziz ur Rehman, Intellectual Property Advisor, Médecins Sans Frontières
Access Campaign



*Joanna Keenan*
Press Officer
Médecins Sans Frontières - Access Campaign
E: joanna.keenan[at]geneva.msf.org
T: twitter.com/joanna_keenan

msfaccess.org
twitter.com/MSF_access
facebook.com/MSFaccess



More information about the Ip-health mailing list